Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer

Dacomitinib (Vizimpro, Pfizer), as monotherapy, is intended for 'the first-line treatment of adult patients with locally advanced or metastatic non-small-cell lung cancer with epidermal growth factor receptor-activating mutations'.

Based on the company submission, dacomitinib is given orally at a dosage of 45 mg until disease progression or unacceptable toxicity. Dacomitinib is available in 3 dose strengths: 45 mg, 30 mg and 15 mg.

The list price is £2,703 for 30×15 mg, 30×30 mg or 30×45 mg capsules.

The company has a commercial arrangement. This makes dacomitinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.